Clinical Trials: Biologics

The 794 clinical trials listed here include 419 that have not yet started recruiting patients or are just now seeking volunteers to participate and another 375 that are active, but not recruiting new patients. This information is potentially valuable to patients still seeking effective treatments for hundreds of diseases, including autoimmune disorders, cancer, cardiovascular diseases, diabetes, infectious diseases, neurological disorders, and many more. It provides a new therapeutic option to discuss with physicians. Those interested in obtaining more information about certain clinical trials can use the URL code listed for each trial to log onto www.clinicaltrials.gov, the clinical tests database of the National Institutes of Health.

Autoimmune Disorders 39 Blood Disorders 34 Cancer 384 Cardiovascular Disease 34 Diabetes 5 Digestive Disorders 18 Eye Disorders 14 Genetic Disorders 16 Infectious Diseases 122 Musculoskeletal Disorders 33 Neurological Disorders 18 Respiratory Diseases 8 Skin Diseases115 15 Transplantation 5 Others 49

Source: www.clinicaltrials.gov; Search criteria: Biological, Phase 0, 1, 2, 3; industry only, United States. Included are only active clinical trials – active, not recruiting; recruiting, not yet recruiting, and enrolling by invitation. Search performed 2/5/2013.

Autoimmune disorders – 39 Active Clinical Trials — Psoriasis is listed under Skin Disorders —

Study 1 – Recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Multiple Sclerosis, Secondary Progressive http://ClinicalTrials.gov/show/NCT01684761

Study 2 – Active, not recruiting A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Scleroderma http://ClinicalTrials.gov/show/NCT00946699

Study 3 – Recruiting A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01526057

Study 4 – Active, not recruiting A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting http://ClinicalTrials.gov/show/NCT00050778

Study 5 – Active, not recruiting An Efficacy and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis (RA) Despite Treatment With Methotrexate, Non Steroidal Pain and/or Corticosteroids Rheumatoid Arthritis

http://ClinicalTrials.gov/show/NCT00973479

Study 6 – Recruiting A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT01484496

Study 7 – Active, not recruiting Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01559103

Study 8 – Active, not recruiting Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01373151

Study 9 – Recruiting Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT01405196

Study 10 – Recruiting Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01359943

Study 11 – Active, not recruiting An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme- Sponsored Studies of Alemtuzumab Multiple Sclerosis, Relapsing-Remitting http://ClinicalTrials.gov/show/NCT00930553

Study 12 – Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis Lupus Nephritis | Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT01639339

Study 13 – Recruiting A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) Juvenile Idiopathic Arthritis http://ClinicalTrials.gov/show/NCT01230827

Study 14 – Active, not recruiting A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT00724867

Study 15 – Active, not recruiting A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01712178

Study 16 – Recruiting A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT01438489

Study 17 – Recruiting Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01519791

Study 18 – Active, not recruiting A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) Juvenile Idiopathic Arthritis http://ClinicalTrials.gov/show/NCT01777399

Study 19 – Recruiting A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01636817

Study 20 – Recruiting Study of Veltuzumab (hA20) at Different Doses in Patients With ITP Idiopathic Thrombocytopenic Purpura http://ClinicalTrials.gov/show/NCT00547066

Study 21 – Active, not recruiting An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS) Multiple Sclerosis, Relapsing Remitting http://ClinicalTrials.gov/show/NCT01462318

Study 22 – Recruiting Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing- Remitting Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting http://ClinicalTrials.gov/show/NCT01585766

Study 23 – Active, not recruiting Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFα Therapies Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT00468546

Study 24 – Active, not recruiting Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01261403

Study 25 – Active, not recruiting Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056 Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01296711

Study 26 – Recruiting IGIV Study for Chronic ITP Patients Ages 3-70 Idiopathic Thrombocytopenic Purpura http://ClinicalTrials.gov/show/NCT00511147

Study 27 – Recruiting A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura Idiopathic Thrombocytopenic Purpura http://ClinicalTrials.gov/show/NCT01071954

Study 28 – Recruiting Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01752855

Study 29 – Active, not recruiting A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02 Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT00583362

Study 30 – Active, not recruiting Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis Pulmonary Sarcoidosis http://ClinicalTrials.gov/show/NCT01440192

Study 31 – Not yet recruiting The Evaluation of Belimumab in Myasthenia Gravis (MG) Myasthenia Gravis http://ClinicalTrials.gov/show/NCT01480596

Study 32 – Active, not recruiting Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT00425932

Study 33 – Recruiting Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01333878

Study 34 – Recruiting

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01351480

Study 35 – Recruiting A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01636843

Study 36 – Recruiting Interventional Study in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim Idiopathic Thrombocytopenic Purpura http://ClinicalTrials.gov/show/NCT01143038

Study 37 – Recruiting Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT01377012

Study 38 – Recruiting Balancing Lupus Experiences With Stress Strategies Systemic Lupus Erythematosus http://ClinicalTrials.gov/show/NCT01351662

Study 39 – Active, not recruiting Abatacept Versus Adalimumab Head-to-Head Rheumatoid Arthritis http://ClinicalTrials.gov/show/NCT00929864

Blood Disorders – 34 Active Clinical Trials

Study 1 – Active, not recruiting Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A Hemophilia A http://ClinicalTrials.gov/show/NCT01029340

Study 2 – Active, not recruiting Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B Hemophilia B http://ClinicalTrials.gov/show/NCT00768287

Study 3 – Recruiting Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Hemophilia A http://ClinicalTrials.gov/show/NCT01619046

Study 4 – Recruiting A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. Anemia http://ClinicalTrials.gov/show/NCT01146574

Study 5 – Active, not recruiting An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure Reversal of Coagulopathy http://ClinicalTrials.gov/show/NCT00803101

Study 6 – Recruiting Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP) Thrombotic Thrombocytopenic Purpura http://ClinicalTrials.gov/show/NCT01151423

Study 7 – Not yet recruiting Belimumab in Remission of VASculitis Vasculitis http://ClinicalTrials.gov/show/NCT01663623

Study 8 – Recruiting Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B- Domain Deleted Recombinant FVIII Hemophilia A http://ClinicalTrials.gov/show/NCT00543439

Study 9 – Active, not recruiting Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment Hemophilia A http://ClinicalTrials.gov/show/NCT00623480

Study 10 – Not yet recruiting Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On- demand Regimen Hemophilia A or B With Factor VIII (FVIII) or Factor IX (FIX) Inhibitors http://ClinicalTrials.gov/show/NCT01757405

Study 11 – Recruiting A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S 303 Treated Red Blood Cells Focus: Assess Post Infusion Viability of S303 RBCs http://ClinicalTrials.gov/show/NCT01711346

Study 12 – Recruiting Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests Reversal of Blood Thinner Use in Healthy Volunteers http://ClinicalTrials.gov/show/NCT01758432

Study 13 – Recruiting Babesia Testing in Blood Donors Transfusion Transmitted Babesiosis http://ClinicalTrials.gov/show/NCT01528449

Study 14 – Recruiting Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B Hemophilia B http://ClinicalTrials.gov/show/NCT01335061

Study 15 – Recruiting Pragmatic, Randomized Optimal Platelets and Plasma Ratios Trauma http://ClinicalTrials.gov/show/NCT01545232

Study 16 – Recruiting

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A Hemophilia A http://ClinicalTrials.gov/show/NCT01486927

Study 17 – Recruiting A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Hemophilia B http://ClinicalTrials.gov/show/NCT01496274

Study 18 – Recruiting A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A Hemophilia A http://ClinicalTrials.gov/show/NCT01580293

Study 19 – Recruiting Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired HemophiliaA Hemophilia A http://ClinicalTrials.gov/show/NCT01178294

Study 20 – Recruiting Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Von Willebrand Disease http://ClinicalTrials.gov/show/NCT01410227

Study 21 – Active, not recruiting Early Prophylaxis Immunologic Challenge (EPIC) Study

Hemophilia A http://ClinicalTrials.gov/show/NCT01376700

Study 22 – Not yet recruiting Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A Hemophilia A http://ClinicalTrials.gov/show/NCT01775618

Study 23 – Active, not recruiting TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery Hemorrhage http://ClinicalTrials.gov/show/NCT01192022

Study 24 – Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial Hemophilia A http://ClinicalTrials.gov/show/NCT01311648

Study 25 – Recruiting Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery Peripheral Vascular Surgical Bleeding http://ClinicalTrials.gov/show/NCT01662856

Study 26 – Recruiting Phase 3 Study of Fibrocaps™ in Surgical Bleeding Mild or Moderate Surgical Bleeding http://ClinicalTrials.gov/show/NCT01527357

Study 27 – Recruiting

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Anemia, Chronic Kidney Disease http://ClinicalTrials.gov/show/NCT01652872

Study 28 – Recruiting Wilate in Subjects With Von Willebrand Disease Who Undergo Major Surgery Prevent Bleeding in Major Surgery http://ClinicalTrials.gov/show/NCT01365546

Study 29 – Recruiting Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Hemophilia B http://ClinicalTrials.gov/show/NCT01687608

Study 30 – Recruiting Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries Soft Tissue Surgical Bleeding http://ClinicalTrials.gov/show/NCT01731938

Study 31 – Recruiting A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B Hemophilia http://ClinicalTrials.gov/show/NCT01708564

Study 32 – Active, not recruiting Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A Hemophilia A http://ClinicalTrials.gov/show/NCT01434511

Study 33 – Not yet recruiting Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers Coagulation Defects http://ClinicalTrials.gov/show/NCT01589666

Study 34 – Recruiting Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries Parenchymous Tissue Surgical Bleeding http://ClinicalTrials.gov/show/NCT01754480

Cancer – 385 Active Clinical Trials

Study 1 – recruiting TNFerade Biologic to Treat Locally Advanced Prostate Cancer http://ClinicalTrials.gov/show/NCT01048151

Study 2 – Recruiting Evaluation of an Anti-cancer Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer http://ClinicalTrials.gov/show/NCT01220128

Study 3 – Active, not recruiting Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01413087

Study 4 – Active, not recruiting Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT00272649

Study 5 – Recruiting Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01213472

Study 6 – Active, not recruiting Evaluation of a New Anti-cancer Immunotherapy After in Adult Patients With Acute Myeloid Leukemia Acute Myeloid Leukemia http://ClinicalTrials.gov/show/NCT00725283

Study 7 – Recruiting Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy Acute Myeloid Leukemia http://ClinicalTrials.gov/show/NCT01051063

Study 8 – Recruiting ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Neuroblastoma http://ClinicalTrials.gov/show/NCT01592045

Study 9 – Recruiting Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma Multiple Myeloma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma http://ClinicalTrials.gov/show/NCT01435720

Study 10 – Active, not recruiting BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT01354431

Study 11 – Recruiting Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01489059

Study 12 – Recruiting A Study of IMC-RON8 in Advanced Solid Tumors Cancer http://ClinicalTrials.gov/show/NCT01119456

Study 13 – Recruiting Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01359657

Study 14 – Active, not recruiting A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies Metastatic Castration-resistant Prostrate Cancer (mCRPC)|Renal Cell Carcinoma (RCC)|Metastatic Melanoma | Non-small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00730639

Study 15 – Recruiting Multiple Ascending Dose (MDX1105-01) Cancer http://ClinicalTrials.gov/show/NCT00729664

Study 16 – Active, not recruiting Open Label Extension Study of Conatumumab (AMG 655) Solid Tumors http://ClinicalTrials.gov/show/NCT01327612

Study 17 – Active, not recruiting Therapy Compared With Alfa in Treating Patients With Stage III Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00003715

Study 18 – Active, not recruiting A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT00728949

Study 19 – Active, not recruiting

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT00629057

Study 20 – Active, not recruiting To Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen Prostate Cancer http://ClinicalTrials.gov/show/NCT00715078

Study 21 – Recruiting Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT01472081

Study 22 – Active, not recruiting Combination Chemotherapy Followed By Vaccine Therapy Plus in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00017290

Study 23 – Recruiting A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT01322490

Study 24 – Active, not recruiting Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Lymphoma

http://ClinicalTrials.gov/show/NCT00003942

Study 25 – Recruiting Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy Epithelial http://ClinicalTrials.gov/show/NCT01521143

Study 26 – Active, not recruiting Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00010309

Study 27 – Active, not recruiting Vaccine Therapy With or Without -2 in Treating Patients With Stage III or Stage IV Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00004025

Study 28 – Recruiting Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01454102

Study 29 – Active, not recruiting Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00769704

Study 30 – Recruiting A Study in Second Line Metastatic Colorectal Cancer http://ClinicalTrials.gov/show/NCT01183780

Study 31 – Active, not recruiting Study for Unresectable Stage III Non-small Cell Lung Cancer Non-small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00409188

Study 32 – Recruiting Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT01335399

Study 33 – Recruiting Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Squamous Cell Carcinoma of the Oral Cavity http://ClinicalTrials.gov/show/NCT01265849

Study 34 – Recruiting Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Prostate Cancer http://ClinicalTrials.gov/show/NCT01487863

Study 35 – Recruiting Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00258336

Study 36 – Active, not recruiting

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Non-small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01504542

Study 37 – Active, not recruiting Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Myelodysplastic Syndromes http://ClinicalTrials.gov/show/NCT00513578

Study 38 – Active, not recruiting Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas Pancreatic Cancer http://ClinicalTrials.gov/show/NCT00003780

Study 39 – Recruiting A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non- metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen- Deprivation Therapy Prostate Cancer http://ClinicalTrials.gov/show/NCT00925600

Study 40 – Recruiting Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients Breast Cancer http://ClinicalTrials.gov/show/NCT01234402

Study 41 – Active, not recruiting

Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma Colorectal Cancer http://ClinicalTrials.gov/show/NCT00813605

Study 42 – Recruiting Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00062907

Study 43 – Recruiting Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00874107

Study 44 – Recruiting Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects Breast Cancer http://ClinicalTrials.gov/show/NCT01516307

Study 45 – Recruiting Trial of a Single ProHema-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies Hematologic Malignancies http://ClinicalTrials.gov/show/NCT01627314

Study 46 – Recruiting A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Cervical Intraepithelial Neoplasia http://ClinicalTrials.gov/show/NCT01304524

Study 47 – Active, not recruiting GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00480025

Study 48 – Active, not recruiting A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non- Small Cell Lung Cancer Non-small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00762034

Study 49 – Active, not recruiting A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT00401843

Study 50 – Recruiting Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence HER2-Negative Breast Cancer http://ClinicalTrials.gov/show/NCT01479244

Study 51 – Recruiting

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib Hepatocellular Carcinoma http://ClinicalTrials.gov/show/NCT01140347

Study 52– Active, not recruiting Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Non-Small-Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00874848

Study 53 – Active, not recruiting A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) Glioblastoma Multiforme http://ClinicalTrials.gov/show/NCT01280552

Study 54 – Active, not recruiting Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00071955

Study 55 – Active, not recruiting Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00005959

Study 56 – Recruiting Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Small Cell Lung Carcinoma http://ClinicalTrials.gov/show/NCT01450761

Study 57 – Recruiting Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder, Urethra, Ureter, or Renal Pelvis Carcinoma Carcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal Pelvis http://ClinicalTrials.gov/show/NCT01282463

Study 58 – Active, not recruiting

Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Lymphoma http://ClinicalTrials.gov/show/NCT00069966

Study 59 – Active, not recruiting With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Melanoma (Skin) http://ClinicalTrials.gov/show/NCT00002767

Study 60 – Active, not recruiting Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Leukemia http://ClinicalTrials.gov/show/NCT00454168

Study 61 – Recruiting Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT01436968

Study 62 – Recruiting Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Melanoma http://ClinicalTrials.gov/show/NCT01546571

Study 63 – Active, not recruiting A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver Hepatocellular Carcinoma http://ClinicalTrials.gov/show/NCT00906373

Study 64 – Active, not recruiting Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Lung Cancer http://ClinicalTrials.gov/show/NCT00104780

Study 65 – Recruiting

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy Lymphoma, Follicular http://ClinicalTrials.gov/show/NCT01200589

Study 66 – Active, not recruiting Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Melanoma http://ClinicalTrials.gov/show/NCT01515189

Study 67 – Active, not recruiting Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free Sarcoma http://ClinicalTrials.gov/show/NCT01141491

Study 68 – Active, not recruiting Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer http://ClinicalTrials.gov/show/NCT01200992

Study 69 – Active, not recruiting Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01471197

Study 70 – Recruiting

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01629758

Study 71 – Recruiting A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer Colorectal Cancer http://ClinicalTrials.gov/show/NCT01111604

Study 72 – Active, not recruiting A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Malignant Solid Tumor | Lymphomas | Multiple Myeloma http://ClinicalTrials.gov/show/NCT00725634

Study 73 – Recruiting Multiple Ascending Dose Hepatocellular Carcinoma http://ClinicalTrials.gov/show/NCT01658878

Study 74 – Recruiting Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer Recurrent Neuroendocrine Carcinoma of the Skin http://ClinicalTrials.gov/show/NCT01440816

Study 75 – Active, not recruiting Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer Kidney Cancer http://ClinicalTrials.gov/show/NCT00003181 Study 76 – Active, not recruiting

Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma Resectable Pancreatic Adenocarcinoma http://ClinicalTrials.gov/show/NCT00600002

Study 77 – Active, not recruiting A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Pancreatic Cancer http://ClinicalTrials.gov/show/NCT01608711

Study 78 – Active, not recruiting Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Leukemia http://ClinicalTrials.gov/show/NCT00024440

Study 79 – Recruiting Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer Solid Tumors http://ClinicalTrials.gov/show/NCT01061840

Study 80 – Active, not recruiting Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT00514072

Study 81 – Recruiting ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia Acute Myeloid Leukemia

http://ClinicalTrials.gov/show/NCT01478074

Study 82 – Recruiting Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma Glioblastoma http://ClinicalTrials.gov/show/NCT01403285

Study 83 – Active, not recruiting Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT00678119 Study 84 – Recruiting Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma Metastatic Melanoma http://ClinicalTrials.gov/show/NCT01621490

Study 85 – Active, not recruiting Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma Metastatic Melanoma http://ClinicalTrials.gov/show/NCT01335009

Study 86 – Active, not recruiting Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00815607

Study 87 – Recruiting

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Liver Cancer http://ClinicalTrials.gov/show/NCT01387555

Study 88 – Recruiting Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Colorectal Cancer http://ClinicalTrials.gov/show/NCT01309126

Study 89 – Recruiting Vaccine Therapy in Treating Patients With Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT00524277

Study 90 – Recruiting Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non- Hodgkin Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00989586

Study 91 – Recruiting Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 Melanoma http://ClinicalTrials.gov/show/NCT01176461

Study 92 – Active, not recruiting Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

Colorectal Cancer http://ClinicalTrials.gov/show/NCT00522665

Study 93 – Active, not recruiting Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558 Melanoma http://ClinicalTrials.gov/show/NCT01176474

Study 94 – Active, not recruiting Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT00779402

Study 95 – Recruiting Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization Melanoma http://ClinicalTrials.gov/show/NCT00338377

Study 96 – Active, not recruiting Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT00068341

Study 97 – Active, not recruiting Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Brain and Central Nervous System Tumors http://ClinicalTrials.gov/show/NCT00895180

Study 98 – Recruiting Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01350401

Study 99 – Not yet recruiting CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission Acute Myelogenous Leukemia http://ClinicalTrials.gov/show/NCT01639456

Study 100 – Active, not recruiting Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo- Astrocytomas Astrocytoma | Oligo-Astrocytoma | Glioma http://ClinicalTrials.gov/show/NCT00795457

Study 101 – Active, not recruiting Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART Melanoma http://ClinicalTrials.gov/show/NCT01008527

Study 102 – Recruiting Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT01361711

Study 103 – Active, not recruiting A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL Leukemia http://ClinicalTrials.gov/show/NCT00858117

Study 104 – Recruiting

Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Leukemia | Multiple Myeloma | Myelodysplastic Syndrome | Non-Hodgkin's Lymphoma http://ClinicalTrials.gov/show/NCT01746849

Study 105 – Recruiting A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients Melanoma http://ClinicalTrials.gov/show/NCT01585350

Study 106 – Recruiting Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT01706458

Study 107 – Active, not recruiting Gene Therapy for Pleural Malignancies Pleural Mesothelioma | Metastatic Pleural Effusions http://ClinicalTrials.gov/show/NCT00299962

Study 108 – Recruiting Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT Non-Hodgkin's Lymphoma | Multiple Myeloma | Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndrome http://ClinicalTrials.gov/show/NCT00709592

Study 109 – Active, not recruiting

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features Neuroendocrine Tumors http://ClinicalTrials.gov/show/NCT00314925

Study 110 – Recruiting Recombinant Vaccinia Virus Administered Intravenously Followed by Intratumoral Boosts in Patients With Metastatic, Refractory Colorectal Carcinoma Colorectal Carcinoma http://ClinicalTrials.gov/show/NCT01394939

Study 111 – Recruiting Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma Unresectable Stage III or IV Melanoma http://ClinicalTrials.gov/show/NCT01397708

Study 112 – Recruiting A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma http://ClinicalTrials.gov/show/NCT01602315

Study 113 – Recruiting A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM) Multiple Myeloma http://ClinicalTrials.gov/show/NCT01602224

Study 114 – Active, not recruiting Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer http://ClinicalTrials.gov/show/NCT01416038

Study 115 – Active, not recruiting Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00030641

Study 116 – Recruiting Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Post-remission Chemotherapy for Leukemia Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplasia http://ClinicalTrials.gov/show/NCT01297543

Study 117 – Active, not recruiting Ph I/II Ipilimumab Vemurafenib Combo Melanoma http://ClinicalTrials.gov/show/NCT01400451

Study 118 – Active, not recruiting A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Advanced Malignancies http://ClinicalTrials.gov/show/NCT00948961

Study 119 – Active, not recruiting Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer Pancreatic Cancer http://ClinicalTrials.gov/show/NCT00603863

Study 120 – Active, not recruiting A Study of IMC-3G3 in Soft Tissue Sarcoma Soft Tissue Sarcoma http://ClinicalTrials.gov/show/NCT01185964

Study 121 – Recruiting Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL Chronic Lymphocytic Lymphoma http://ClinicalTrials.gov/show/NCT00603668

Study 122 – Recruiting A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis http://ClinicalTrials.gov/show/NCT01326871

Study 123 – Recruiting A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma Malignant Glioma http://ClinicalTrials.gov/show/NCT01156584

Study 124 – recruiting Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Non-Hodgkin Lymphoma | Chronic Lymphocytic Lymphoma http://ClinicalTrials.gov/show/NCT00546793

Study 125 – Recruiting Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer Ovarian Cancer http://ClinicalTrials.gov/show/NCT00660101

Study 126 – Recruiting A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases T-cell Lymphomas | T-cell Leukemia | Sezary Syndrome | Mycosis Fungoides http://ClinicalTrials.gov/show/NCT00611208

Study 127 – Not yet recruiting

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Lymphoma http://ClinicalTrials.gov/show/NCT01744223

Study 128 – Recruiting A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Non-muscle Invasive Bladder Cancer http://ClinicalTrials.gov/show/NCT01625260

Study 129 – Active, not recruiting Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA Colon Cancer | Lung Cancer | Breast Cancer http://ClinicalTrials.gov/show/NCT01147965

Study 130 – Active, not recruiting Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT00003183

Study 131 – Active, not recruiting First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT0098105

Study 132 – Active, not recruiting A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT00689507

Study 133 – Recruiting Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT01478048

Study 134 – Active, not recruiting A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma Hematologic Cancer http://ClinicalTrials.gov/show/NCT00742560

Study 135 – Active, not recruiting A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. Bone Metastases in Subjects With Advanced Breast Cancer http://ClinicalTrials.gov/show/NCT00321464

Study 136 – Enrolling by invitation Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function Multiple Myeloma http://ClinicalTrials.gov/show/NCT01393964

Study 137 – Active, not recruiting A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non- small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01168973

Study 138 – Recruiting Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Smoldering Multiple Myeloma http://ClinicalTrials.gov/show/NCT01441973

Study 139 – Recruiting Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC Metastatic Clear-cell Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT01668784

Study 140 – Active, not recruiting Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT01239797

Study 141 – Recruiting Clinical Study of WT2725 in Patients With Advanced Solid Malignancies Cancer http://ClinicalTrials.gov/show/NCT01621542

Study 142 – Recruiting A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

Acute Myeloid Leukemia http://ClinicalTrials.gov/show/NCT01632852

Study 143 – Recruiting A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01608867

Study 144 – Recruiting Safety Study of MGAH22 in HER2-positive Carcinomas Breast Cancer | Gastric Cancer | Bladder Cancer | Ovarian Cancer | Non-small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01148849

Study 145 – Recruiting A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients Colorectal Cancer http://ClinicalTrials.gov/show/NCT01300858

Study 146 – Active, not recruiting IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Metastatic Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT01265901

Study 147 – Active, not recruiting A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00918203

Study 148 – Active, not recruiting Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT00715104

Study 149 – Recruiting Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Squamous Cell Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01642004

Study 150 – Recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Cutaneous T-Cell Lymphoma http://ClinicalTrials.gov/show/NCT01728805

Study 151 – Recruiting A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors Malignant Solid Tumors http://ClinicalTrials.gov/show/NCT01515306

Study 152 – Active, not recruiting Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00676507

Study 153 – Active, not recruiting Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma http://ClinicalTrials.gov/show/NCT01258608

Study 154 – Active, not recruiting Ovarian Cancer Vaccine for Patients in Remission Epithelial Ovarian Cancer http://ClinicalTrials.gov/show/NCT01068509

Study 155 – Active, not recruiting A Study of IMC-A12 in Islet Cell Cancer Carcinoma | Neuroendocrine Tumors http://ClinicalTrials.gov/show/NCT00781911

Study 156 – Active, not recruiting

A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00925314

Study 157 – Active, not recruiting Docetaxel and Vinorelbine Plus in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Lung Cancer http://ClinicalTrials.gov/show/NCT00006215

Study 158 – Active, not recruiting A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Adenocarcinoma of the Lung http://ClinicalTrials.gov/show/NCT01218516

Study 159 – Active, not recruiting Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer Bone Metastases http://ClinicalTrials.gov/show/NCT00321620

Study 160 – Active, not recruiting Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Kidney Cancer http://ClinicalTrials.gov/show/NCT00087022

Study 161 – Recruiting DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Urothelial Carcinoma http://ClinicalTrials.gov/show/NCT01353222

Study 162 – Active, not recruiting Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT01520922

Study 163 – Active, not recruiting Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma Low-Grade Lymphoma http://ClinicalTrials.gov/show/NCT00036426

Study 164 – Active, not recruiting Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer Colorectal Cancer http://ClinicalTrials.gov/show/NCT00062426

Study 165 – Active, not recruiting Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer Breast Cancer

http://ClinicalTrials.gov/show/NCT00703326Study 422

Study 166 – Active, not recruiting Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Non-Hodgkin Lymphoma http://ClinicalTrials.gov/show/NCT00026429

Study 167 – Active, not recruiting Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study Epithelial Ovarian Cancer http://ClinicalTrials.gov/show/NCT01617629

Study 168 – Active, not recruiting Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma http://ClinicalTrials.gov/show/NCT00041730

Study 169 – Active, not recruiting Vaccine Therapy for Patients With Stage III Melanoma Malignant Melanoma http://ClinicalTrials.gov/show/NCT00052130

Study 170 – Active, not recruiting Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes Cancer | Solid Tumors http://ClinicalTrials.gov/show/NCT01017731

Study 171 – Active, not recruiting A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) Acute Myelogenous Leukemia http://ClinicalTrials.gov/show/NCT00510133

Study 172 – Active, not recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Waldenstrom Macroglobulinaemia http://ClinicalTrials.gov/show/NCT00811733

Study 173 – Active, not recruiting A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT01427933

Study 174 – Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy Fallopian Tube Cancer | Ovarian Cancer | Primary Peritoneal Cavity Cancer http://ClinicalTrials.gov/show/NCT00003634

Study 175 – Active, not recruiting Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Metastatic Melanoma http://ClinicalTrials.gov/show/NCT00039234

Study 176 – Active, not recruiting Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer Kidney Cancer http://ClinicalTrials.gov/show/NCT00656734

Study 177 – Active, not recruiting A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer Ovarian Neoplasms http://ClinicalTrials.gov/show/NCT00913835

Study 178 – Recruiting Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy Leukemia | Lymphoma | Multiple Myeloma | Plasma Cell Neoplasm | Myelodysplastic Syndromes

http://ClinicalTrials.gov/show/NCT00891137

Study 179 – Active, not recruiting ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2- 06/N063D Breast Cancer http://ClinicalTrials.gov/show/NCT00490139

Study 180 – Active, not recruiting Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum- Refractory Head and Neck Cancers Squamous Cell Carcinoma of the Head and Neck http://ClinicalTrials.gov/show/NCT01166542

Study 181 – Recruiting A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) Non-Small-Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01160744

Study 182 – Active, not recruiting Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Leukemia http://ClinicalTrials.gov/show/NCT00006045

Study 183 – Active, not recruiting Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia Cervical Intraepithelial Neoplasia http://ClinicalTrials.gov/show/NCT00493545

Study 184 – Recruiting An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ Cervical Intraepithelial Neoplasia http://ClinicalTrials.gov/show/NCT01116245

Study 185 – Recruiting A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01577745

Study 186 – Recruiting Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma Malignant Melanoma http://ClinicalTrials.gov/show/NCT01696045

Study 187 – Recruiting A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy Metastatic Melanoma http://ClinicalTrials.gov/show/NCT01721746

Study 188 – Active, not recruiting

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer Ovarian Neoplasms | Breast Neoplasms | Prostatic Neoplasms http://ClinicalTrials.gov/show/NCT01095848

Study 189 – Active, not recruiting Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Myelodysplastic Syndromes http://ClinicalTrials.gov/show/NCT00017550

Study 190 – Active, not recruiting Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer Pancreas Cancer http://ClinicalTrials.gov/show/NCT00300950

Study 191 – Recruiting A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma Malignant Melanoma http://ClinicalTrials.gov/show/NCT01227551

Study 192 – Recruiting Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01673854

Study 193 – Active, not recruiting Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure Bladder Cancer http://ClinicalTrials.gov/show/NCT00109655

Study 194 – Recruiting A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI Solid Tumors http://ClinicalTrials.gov/show/NCT01634555

Study 195 – Active, not recruiting Vaccine Therapy for Patients With Stage IV Melanoma Malignant Melanoma http://ClinicalTrials.gov/show/NCT00052156

Study 196 – Active, not recruiting Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Head and Neck Cancer http://ClinicalTrials.gov/show/NCT00003257

Study 197 – Active, not recruiting Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter http://ClinicalTrials.gov/show/NCT00005958

Study 198 – Recruiting Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01611558

Study 199 – Active, not recruiting Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma Bone Metastases http://ClinicalTrials.gov/show/NCT00330759

Study 200 – Active, not recruiting Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Prostate Cancer http://ClinicalTrials.gov/show/NCT00005960

Study 201 – Active, not recruiting PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Pancreatic Cancer http://ClinicalTrials.gov/show/NCT00088660

Study 202 – Active, not recruiting A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer Stomach Cancer | Esophageal Cancer http://ClinicalTrials.gov/show/NCT01246960

Study 203 – Active, not recruiting Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Recurrent Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

http://ClinicalTrials.gov/show/NCT01381861

Study 204 – Active, not recruiting Study of Ramucirumab in Ovarian Cancer Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma http://ClinicalTrials.gov/show/NCT00721162

Study 205 – Active, not recruiting A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00942162

Study 206 – Active, not recruiting A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma Gastric Cancer http://ClinicalTrials.gov/show/NCT01170663

Study 207 – Active, not recruiting A Study of Ramucirumab and Docetaxel in Patients With Solid Tumors Malignant Solid Tumors http://ClinicalTrials.gov/show/NCT01567163

Study 208 – Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer Fallopian Tube Cancer | Ovarian Cancer | Primary Peritoneal Cavity Cancer http://ClinicalTrials.gov/show/NCT00004064

Study 209 – Active, not recruiting Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01159964

Study 210 – Recruiting Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects Oral Mucositis http://ClinicalTrials.gov/show/NCT01403064

Study 211 – Recruiting KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Adult T-cell Leukemia-Lymphoma http://ClinicalTrials.gov/show/NCT01626664

Study 212 – Recruiting A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01624467

Study 213 – Recruiting Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01673867

Study 214 – Recruiting Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Adenocarcinoma|Her2+|Advanced Metastatic Breast Cancer|Metastatic ErbB2|Invasive Breast Advanced Breast Cancer http://ClinicalTrials.gov/show/NCT00968968

Study 215 – Active, not recruiting A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma Metastatic Melanoma http://ClinicalTrials.gov/show/NCT00395070

Study 216 – Recruiting Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy Non-Hodgkin's Lymphoma | Hodgkin Lymphoma | Multiple Myeloma | Chronic Myelogenous Leukemia http://ClinicalTrials.gov/show/NCT01592370

Study 217 – Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Metastatic Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT01582672

Study 218 – Recruiting Study of Patients With Advanced Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00948675

Study 219 – Recruiting

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT01039376

Study 220 – Enrolling by invitation An Extended Use Study of Safety and Efficacy of OncoVEXGM-CSF in Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01368276

Study 221 – Recruiting Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Non-Hodgkin Lymphoma http://ClinicalTrials.gov/show/NCT01294579

Study 222 – Recruiting Immunotherapy Study for Surgically Resected Pancreatic Cancer Pancreatic Cancer http://ClinicalTrials.gov/show/NCT01072981

Study 223 – Active, not recruiting Vaccine Therapy in Treating Patients With Malignant Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00128583

Study 224 – Active, not recruiting Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Patients With Gastric Cancer and Adenocarcinoma

Gastric Cancer | Adenocarcinoma http://ClinicalTrials.gov/show/NCT00917384

Study 225 – Active, not recruiting PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Prostate Cancer http://ClinicalTrials.gov/show/NCT00078585

Study 226 – Active, not recruiting Vaccine Study for Surgically Resected Pancreatic Cancer Pancreatic Cancer http://ClinicalTrials.gov/show/NCT00569387

Study 227 – Active, not recruiting Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia Leukemia http://ClinicalTrials.gov/show/NCT00003991

Study 228 – Active, not recruiting Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer Metastatic Pancreatic Cancer http://ClinicalTrials.gov/show/NCT01272791

Study 229 – Active, not recruiting Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer Prostatic Cancer http://ClinicalTrials.gov/show/NCT01431391

Study 230 – Recruiting A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung Metastatic or Recurrent Squamous Cell Carcinoma of the Lung http://ClinicalTrials.gov/show/NCT00998192

Study 231 – Active, not recruiting A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment Non-Hodgkin's Lymphoma http://ClinicalTrials.gov/show/NCT01007292

Study 232 – Recruiting Study of ACE-041 in Patients With Squamous Cell Carcinoma of the Head and Neck Squamous Cell Carcinoma of the Head and Neck http://ClinicalTrials.gov/show/NCT01458392

Study 233 – Recruiting Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Glioblastoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Oligoastrocytoma http://ClinicalTrials.gov/show/NCT01470794

Study 234 – Active, not recruiting Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma Advanced Solid Tumors | Multiple Myeloma http://ClinicalTrials.gov/show/NCT00996957

Study 235 – Recruiting A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Locally Advanced Malignant Neoplasm | Malignant Solid Tumour http://ClinicalTrials.gov/show/NCT01325558

Study 236 – Active, not recruiting Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) Malignant Glioma http://ClinicalTrials.gov/show/NCT00589875

Study 237 – Active, not recruiting Open Label Extension In Cancer Patients Neoplasms | Bone Metastases http://ClinicalTrials.gov/show/NCT00830180

Study 238 – Recruiting Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Malignant Solid Tumors http://ClinicalTrials.gov/show/NCT01765790

Study 239 – Active, not recruiting Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma Grade IV Glioma | Grade IV Astrocytoma | Glioblastoma Multiforme http://ClinicalTrials.gov/show/NCT01290692

Study 240 – Recruiting A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01345201

Study 241 – Recruiting A Study of IMC-TR1 in Patients With Advanced Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01646203

Study 242 – Active, not recruiting A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT01219010

Study 243 – Active, not recruiting AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) Pancreatic Cancer http://ClinicalTrials.gov/show/NCT00638612

Study 244 – Recruiting Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Solid Tumor Malignancies http://ClinicalTrials.gov/show/NCT01118819

Study 245 – Recruiting A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia Hairy Cell Leukemia

http://ClinicalTrials.gov/show/NCT00586924

Study 246 – Active, not recruiting Study of REOLYSIN® in Combination With FOLFIRI in Patients With Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer Colorectal Cancer http://ClinicalTrials.gov/show/NCT01274624

Study 247 – Active, not recruiting Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit Non-Hodgkin's Lymphoma | Hodgkin's Disease | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Acute Lymphoblastic Leukemia http://ClinicalTrials.gov/show/NCT01527838

Study 248 – Recruiting Safety Study of MGA271 in Refractory Cancer Prostate Cancer | Pancreatic Cancer | Melanoma | Renal Cell Carcinoma | Ovarian Cancer | Colorectal Cancer | Gastric Cancer | Bladder Cancer | Non-Small Cell Lung Cancer | Glioblastoma http://ClinicalTrials.gov/show/NCT01391143

Study 249 – Recruiting A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine- Cisplatin Malignant Solid Tumors http://ClinicalTrials.gov/show/NCT01606748

Study 250 – Active, not recruiting Autologous Vaccine for Follicular Lymphoma Follicular Lymphoma http://ClinicalTrials.gov/show/NCT01022255

Study 251 – Recruiting A Study of IMC-CS4 in Subjects With Advanced Solid Tumors Neoplasms http://ClinicalTrials.gov/show/NCT01346358

Study 252 – Recruiting A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01603979

Study 253 – Recruiting An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction http://ClinicalTrials.gov/show/NCT01585987

Study 254 – Recruiting A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Neoplasms http://ClinicalTrials.gov/show/NCT01288989

Study 255 – Recruiting A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Ovarian Neoplasms http://ClinicalTrials.gov/show/NCT01616303

Study 256 – Active, not recruiting

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT01025206

Study 257 – Active, not recruiting Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 NY-ESO-1 Positive-Advanced Solid Tumors http://ClinicalTrials.gov/show/NCT01234012

Study 258 – Recruiting Evaluation of TRC105 In The Treatment Of Recurrent Glioblastoma After Prior Antiangiogenic Therapy (Including Anti-VEGF Therapy) Glioblastoma Multiforme http://ClinicalTrials.gov/show/NCT01564914

Study 259 – Active, not recruiting Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT00753220

Study 260 – Active, not recruiting A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma http://ClinicalTrials.gov/show/NCT00998322

Study 261 – Active, not recruiting Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma Brain and Central Nervous System Tumors http://ClinicalTrials.gov/show/NCT00052624

Study 262 – Recruiting Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non- Small Cell Lung Cancer With KRAS or EGFR Activation Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00861627

Study 263 – Recruiting Sym004 in Patients With Advanced Solid Tumors Metastatic Colorectal Cancer http://ClinicalTrials.gov/show/NCT01117428

Study 264 – Active, not recruiting Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma Head and Neck Cancer http://ClinicalTrials.gov/show/NCT00753038

Study 265 – Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT01644253

Study 266 – Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1) Acute Myeloid Leukemia http://ClinicalTrials.gov/show/NCT01520558

Study 267 – Active, not recruiting Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00016263

Study 268 – Recruiting CRS-207 Cancer Vaccine in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma http://ClinicalTrials.gov/show/NCT01675765

Study 269 – Active, not recruiting Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas Malignant Gliomas http://ClinicalTrials.gov/show/NCT00751270

Study 270 – Not yet recruiting Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01774578

Study 271 – Recruiting Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Hematological Malignancies | Leukemia | Lymphoma http://ClinicalTrials.gov/show/NCT01474681

Study 272 – Recruiting A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma Relapsed or Refractory Multiple Myeloma http://ClinicalTrials.gov/show/NCT01670994

Study 273 – Active, not recruiting First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00982111

Study 274 – Recruiting Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Mantle Cell Lymphoma http://ClinicalTrials.gov/show/NCT01437709

Study 275 – Active, not recruiting Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma and Plasma Cell Neoplasm http://ClinicalTrials.gov/show/NCT00017602

Study 276 – Active, not recruiting Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer Prostate Cancer http://ClinicalTrials.gov/show/NCT01197209

Study 277 – Recruiting Open Label Study to Evaluate the Safety and Tolerability of GI-6301 a Vaccine Consisting of Whole Heat-Killed Recombinant Yeast Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01519817

Study 278 – Active, not recruiting Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer Solid Tumors http://ClinicalTrials.gov/show/NCT00550927

Study 279 – Recruiting Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer Ovarian Cancer http://ClinicalTrials.gov/show/NCT01309230

Study 280 – Recruiting Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Malignant Melanoma or Solid Tumors http://ClinicalTrials.gov/show/NCT01239134

Study 281 – Active, not recruiting Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Leukemia | Lymphoma http://ClinicalTrials.gov/show/NCT00551239

Study 282 – Recruiting

Salvage Ovarian FANG Vaccine + Bevacizumab Ovarian Cancer http://ClinicalTrials.gov/show/NCT01551745

Study 283 – Recruiting Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Breast Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasms | Pancreatic Neoplasms | Stomach Neoplasms http://ClinicalTrials.gov/show/NCT01384253

Study 284 – Recruiting Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer Advanced Cancer | Metastatic Cancer http://ClinicalTrials.gov/show/NCT01505153

Study 285 – Active, not recruiting A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00655161

Study 286 – Recruiting Phase II FANG in Advanced Melanoma Advanced Melanoma http://ClinicalTrials.gov/show/NCT01453361

Study 287 – Not yet recruiting Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Melanoma http://ClinicalTrials.gov/show/NCT01709162

Study 288 – Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00014664

Study 289 – Recruiting Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Metastatic Melanoma http://ClinicalTrials.gov/show/NCT00984464

Study 290 – Recruiting Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases Colon Cancer http://ClinicalTrials.gov/show/NCT01505166

Study 291 – Recruiting Monoclonal Antibody hA20 in Treating Patients With Refractory Non-Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00112970

Study 292 – Recruiting Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks

Melanoma http://ClinicalTrials.gov/show/NCT01636882

Study 293 – Recruiting Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer Head and Neck Cancer http://ClinicalTrials.gov/show/NCT01584284

Study 294 – Active, not recruiting A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT00772486

Study 295 – Recruiting Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Superficial Bladder Cancer http://ClinicalTrials.gov/show/NCT00595088

Study 296 – Active, not recruiting Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia Leukemia http://ClinicalTrials.gov/show/NCT00017589

Study 297 – Recruiting

Phase 1 Study of ONT-10 in Patients With Solid Tumors Solid Tumors http://ClinicalTrials.gov/show/NCT01556789

Study 298 – Active, not recruiting A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy Breast Cancer http://ClinicalTrials.gov/show/NCT01152398

Study 299 – Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Gastrointestinal Carcinoid Tumor | Islet Cell Tumor | Lung Cancer | Neoplastic Syndrome | Neuroendocrine Tumor http://ClinicalTrials.gov/show/NCT00227617

Study 300 – Active, not recruiting Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia http://ClinicalTrials.gov/show/NCT00983528

Study 301 – Active, not recruiting Redirected Auto T Cells for Advanced Myeloma Myeloma http://ClinicalTrials.gov/show/NCT01352286

Study 302 – Recruiting Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Colorectal Cancer http://ClinicalTrials.gov/show/NCT00940316

Study 303 – Active, not recruiting Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome Lymphoma http://ClinicalTrials.gov/show/NCT00057967

Study 304– Recruiting Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma Myeloma http://ClinicalTrials.gov/show/NCT00698776

Study 305 – Active, not recruiting Bevacizumab in Treating Patients With Angiosarcoma Sarcoma http://ClinicalTrials.gov/show/NCT00288015

Study 306 – Active, not recruiting Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT00654836

Study 307 – Active, not recruiting

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Osteosarcoma http://ClinicalTrials.gov/show/NCT00667342

Study 308 – Recruiting A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver Metastatic Colorectal Cancer http://ClinicalTrials.gov/show/NCT00803647

Study 309 – Active, not recruiting Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT00667251

Study 310 – Active, not recruiting HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM Brain and Central Nervous System Tumors http://ClinicalTrials.gov/show/NCT00905060

Study 311 – Recruiting Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders Nonmalignant Neoplasm http://ClinicalTrials.gov/show/NCT00919503

Study 312 – Active, not recruiting Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer Breast Cancer http://ClinicalTrials.gov/show/NCT01423123

Study 313 – Recruiting MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Multiple Myeloma http://ClinicalTrials.gov/show/NCT01380145

Study 314 – Recruiting Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors Cancer Survivor | Human Papilloma Virus Infection http://ClinicalTrials.gov/show/NCT01492582

Study 315 – Recruiting Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Stage IV Colorectal Cancer http://ClinicalTrials.gov/show/NCT01652196

Study 316 – Active, not recruiting Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy B-Cell Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT00800943

Study 317 – Recruiting

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma Giant Cell Glioblastoma | Glioblastoma | Gliosarcoma http://ClinicalTrials.gov/show/NCT01149850

Study 318 – Recruiting Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00720876

Study 319 – Recruiting Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Urothelial Carcinoma http://ClinicalTrials.gov/show/NCT01437488

Study 320 – Recruiting Trial of pIL-12 Electroporation Malignant Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01502293

Study 321 – Active, not recruiting GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Prostate Cancer http://ClinicalTrials.gov/show/NCT00122005

Study 322 – Recruiting Immunization of Patients With Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00793208

Study 323 – Active, not recruiting Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression Breast Cancer http://ClinicalTrials.gov/show/NCT00033514

Study 324 – Recruiting A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer Squamous Cell Carcinoma http://ClinicalTrials.gov/show/NCT00660218

Study 325 – Recruiting S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Multiple Myeloma http://ClinicalTrials.gov/show/NCT01668719

Study 326 – Active, not recruiting Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders Lymphoproliferative Disorder http://ClinicalTrials.gov/show/NCT00869323

Study 327 – Active, not recruiting Safety Study of Adjuvant Vaccine to Treat Melanoma Patients Melanoma http://ClinicalTrials.gov/show/NCT01079741

Study 328 – Recruiting

A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Synovial Sarcoma http://ClinicalTrials.gov/show/NCT01343043

Study 329 – Recruiting Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients HPV-related Head and Neck Cancer http://ClinicalTrials.gov/show/NCT01493154

Study 330 – Active, not recruiting The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma Metastatic Melanoma http://ClinicalTrials.gov/show/NCT00626860

Study 331 – Recruiting Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients Leukemia http://ClinicalTrials.gov/show/NCT01756677

Study 332 – Active, not recruiting Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00244985

Study 333 – Active, not recruiting Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT00947388

Study 334 – Recruiting Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma http://ClinicalTrials.gov/show/NCT01004991

Study 335 – Recruiting Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma Follicular Lymphoma http://ClinicalTrials.gov/show/NCT01147393

Study 336 – Recruiting Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL Non-Hodgkin Lymphoma http://ClinicalTrials.gov/show/NCT01397591

Study 337 – Active, not recruiting Universal GM-CSF-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00101101

Study 338 – Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission Acute Myelogenous Leukemia

http://ClinicalTrials.gov/show/NCT01096602

Study 339 – Recruiting High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI Melanoma http://ClinicalTrials.gov/show/NCT01266603

Study 340 – Active, not recruiting Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma | Follicular Lymphoma | Diffuse Large Cell Lymphoma | Mantle Cell Lymphoma | Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia http://ClinicalTrials.gov/show/NCT00942409

Study 341 – Active, not recruiting Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma http://ClinicalTrials.gov/show/NCT00849524

Study 342 – Active, not recruiting Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Kidney Cancer http://ClinicalTrials.gov/show/NCT00601926

Study 343 – Recruiting Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma Lymphoma http://ClinicalTrials.gov/show/NCT00848328

Study 344 – Active, not recruiting Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Head and Neck Cancer http://ClinicalTrials.gov/show/NCT00423930

Study 345 – Recruiting Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) Leukemia http://ClinicalTrials.gov/show/NCT00840931

Study 346 – Recruiting Panitumumab and Gemcitabine in Relapsed Ovarian Cancer Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer http://ClinicalTrials.gov/show/NCT01296035

Study 347 – Active, not recruiting Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Non-Small Cell Lung Cancer | Head and Neck Cancer http://ClinicalTrials.gov/show/NCT01528137

Study 348 – Recruiting Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma Lung Cancer http://ClinicalTrials.gov/show/NCT01766739

Study 349 – Active, not recruiting A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer Ovarian Cancer | Peritoneal Cancer http://ClinicalTrials.gov/show/NCT00683241

Study 350 – Recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma Diffuse Large Cell Lymphoma | Mantle Cell Lymphoma | Indolent Non-Hodgkin Lymphoma http://ClinicalTrials.gov/show/NCT01479842

Study 351 – Active, not recruiting Bevacizumab and Docetaxel in Treating Older Patients With Stage III-IV Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01665443

Study 352 – Active, not recruiting Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Leukemia http://ClinicalTrials.gov/show/NCT00096044

Study 353 – Active, not recruiting A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00746746

Study 354 – Recruiting Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI Melanoma http://ClinicalTrials.gov/show/NCT01425749

Study 355 – Recruiting Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non- Squamous Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT00655850

Study 356 – Active, not recruiting Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) Leukemia http://ClinicalTrials.gov/show/NCT00415857

Study 357 – Active, not recruiting Docetaxel, Cisplatin, , and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer http://ClinicalTrials.gov/show/NCT01557959

Study 358 – Recruiting Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma Mantle Cell Lymphoma http://ClinicalTrials.gov/show/NCT01472562

Study 359 – Recruiting Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies Leukemia | Myelodysplastic Syndrome http://ClinicalTrials.gov/show/NCT00672165

Study 360 – Recruiting Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission Multiple Myeloma http://ClinicalTrials.gov/show/NCT01349569

Study 361 – Recruiting Umbilical Cord Transplantation for the Elderly Population Hematologic Malignancies http://ClinicalTrials.gov/show/NCT01484470

Study 362 – Not yet recruiting Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma Diffuse Large Cell Lymphoma http://ClinicalTrials.gov/show/NCT01539174

Study 363 – Recruiting Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01125176

Study 364 – Active, not recruiting Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Melanoma http://ClinicalTrials.gov/show/NCT00471887

Study 365 – Recruiting Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Malignant Melanoma http://ClinicalTrials.gov/show/NCT01211262

Study 366 – Recruiting Pilot Study of IFN α2b for Melanoma Patients Melanoma http://ClinicalTrials.gov/show/NCT00871533

Study 367 – Recruiting Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma Malignant Melanoma | Neoplasm Metastasis http://ClinicalTrials.gov/show/NCT00116363

Study 368– Active, not recruiting Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies Non-hematologic Malignancies http://ClinicalTrials.gov/show/NCT00641160

Study 369 – Recruiting MSB0010718C in Solid Tumors

Solid Tumors http://ClinicalTrials.gov/show/NCT01772004

Study 370 – Active, not recruiting Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma http://ClinicalTrials.gov/show/NCT01336933

Study 371 – Active, not recruiting Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) Breast Cancer http://ClinicalTrials.gov/show/NCT00095706

Study 372 – Recruiting Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun- damaged Melanoma Melanoma http://ClinicalTrials.gov/show/NCT01092728

Study 373 – Recruiting A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas Gastrointestinal Adenocarcinomas http://ClinicalTrials.gov/show/NCT01284231

Study 374 – Active, not recruiting Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma Malignant Glioma http://ClinicalTrials.gov/show/NCT00591058

Study 375 – Enrolling by invitation A Rollover Protocol for Subjects Previously Treated With AGS-003 Renal Cell Carcinoma http://ClinicalTrials.gov/show/NCT01482949

Study 376 – Recruiting Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors Malignant Solid Tumors http://ClinicalTrials.gov/show/NCT01632696

Study 377 – Active, not recruiting Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Gastric Cancer | Stomach Cancer http://ClinicalTrials.gov/show/NCT00857246

Study 378 – Recruiting BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non-Small Cell Lung Cancer Lung Cancer http://ClinicalTrials.gov/show/NCT01263782

Study 379 – Active, not recruiting Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer Colorectal Cancer | Neoplasm Metastasis http://ClinicalTrials.gov/show/NCT00444678

Study 380 – Recruiting

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma http://ClinicalTrials.gov/show/NCT01091259

Study 381 – Recruiting A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA) Breast Cancer http://ClinicalTrials.gov/show/NCT01419197

Study 382 – Recruiting Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy Breast Cancer http://ClinicalTrials.gov/show/NCT00999804

Study 383 – Recruiting A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Midline Carcinoma http://ClinicalTrials.gov/show/NCT01587703

Study 384 – Recruiting Bevacizumab Beyond Progression (BBP) Malignant Glioma | Grade 4 Malignant Glioma | Glioblastoma | Gliosarcoma http://ClinicalTrials.gov/show/NCT01740258

Cardiovascular Disease – 34 Active Clinical trials

Study 1 – Recruiting The Fibrin Pad Cardiovascular Study Cardiovascular Disease http://ClinicalTrials.gov/show/NCT01681030

Study 2 – Recruiting A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects Hypercholesterolemia http://ClinicalTrials.gov/show/NCT01720537

Study 3 – Recruiting Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) Intermittent Claudication | Peripheral Artery Disease http://ClinicalTrials.gov/show/NCT01679990

Study 4 – Recruiting Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia Critical Limb Ischemia http://ClinicalTrials.gov/show/NCT01410331

Study 5 – Active, not recruiting A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

Heart Failure http://ClinicalTrials.gov/show/NCT00721045

Study 6 – Recruiting Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. Ischemic Heart Failure http://ClinicalTrials.gov/show/NCT01643590

Study 7 – Active, not recruiting To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction Congestive Heart Failure http://ClinicalTrials.gov/show/NCT00526253

Study 8 – Recruiting Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina Chronic Myocardial Ischemia | Refractory Angina Pectoris | (Advanced) Coronary Heart Disease http://ClinicalTrials.gov/show/NCT01508910

Study 9 – Active, not recruiting A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients Stable Atherothrombotic Disease http://ClinicalTrials.gov/show/NCT01499420

Study 10 – Recruiting A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion Acute Peripheral Arterial Occlusion http://ClinicalTrials.gov/show/NCT01222117

Study 11 – Recruiting Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities Homozygous Familial Hypercholesterolemia http://ClinicalTrials.gov/show/NCT01588496

Study 12 – Recruiting Study to Examine the Effects of MultiStem in Ischemic Stroke

Ischemic Stroke http://ClinicalTrials.gov/show/NCT01436487

Study 13 – Not yet recruiting Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System Ischemic Cardiomyopathy http://ClinicalTrials.gov/show/NCT00626314

Study 14 – Active, not recruiting Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins Atherosclerosis http://ClinicalTrials.gov/show/NCT01587365

Study 15 – Not yet recruiting Patients With Intermittent Claudication Injected With ALDH Bright Cells Peripheral Arterial Disease | Intermittent Claudication http://ClinicalTrials.gov/show/NCT01774097

Study 16 – Recruiting A Study of Modified Stem Cells in Stable Ischemic Stroke Chronic Ischemic Stroke http://ClinicalTrials.gov/show/NCT01287936

Study 17 – Recruiting Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration Myocardial Infarction http://ClinicalTrials.gov/show/NCT01458405

Study 18 – Recruiting

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke Ischemic Stroke http://ClinicalTrials.gov/show/NCT01297413

Study 19 – Active, not recruiting Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD) Peripheral Arterial Disease (PAD)|Claudication http://ClinicalTrials.gov/show/NCT00390767

Study 20 – Recruiting Feasibility Study of BMAC Enhanced CABG Congestive Heart Failure http://ClinicalTrials.gov/show/NCT01074099

Study 21 – Recruiting Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 Hereditary Angioedema http://ClinicalTrials.gov/show/NCT01095510

Study 22 – Recruiting Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects Ischemic Stroke http://ClinicalTrials.gov/show/NCT01273337

Study 23 – Active, not recruiting Study to Assess the Tolerability and Efficacy of AMG 145 in Patients With Hypercholesterolemia Unable to Tolerate an Effective Dose of a Statin. Hyperlipidemia http://ClinicalTrials.gov/show/NCT01375764

Study 24 – Recruiting AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction ST Segment Elevation Myocardial Infarction http://ClinicalTrials.gov/show/NCT01495364

Study 25 – Recruiting An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) Ischemic Dilated Cardiomyopathy http://ClinicalTrials.gov/show/NCT01670981

Study 26 – Recruiting An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) Critical Limb Ischemia http://ClinicalTrials.gov/show/NCT01483898

Study 27 – Active, not recruiting Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy Dilated Cardiomyopathy http://ClinicalTrials.gov/show/NCT01020968

Study 28 – Not yet recruiting

Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia Peripheral Vascular Diseases http://ClinicalTrials.gov/show/NCT01558908

Study 29 – Not yet recruiting A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) ST Segment Elevation Myocardial Infarction | Allogeneic Mesenchymal Bone Marrow Cells http://ClinicalTrials.gov/show/NCT01770613

Study 30 – Active, not recruiting Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke Ischemic Stroke http://ClinicalTrials.gov/show/NCT01310114

Study 31 – Active, not recruiting Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI) Heart Disease | Blocked Arteries | Coronary Ischemia | Coronary Disease | Coronary Artery Disease | Coronary Atherosclerosis http://ClinicalTrials.gov/show/NCT00790764

Study 32 – Not yet recruiting IVIG in Acute Ischemic Stroke: A Pilot Study Ischemic Stroke http://ClinicalTrials.gov/show/NCT01628055

Study 33 – Active, not recruiting Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br) Coronary Artery Disease http://ClinicalTrials.gov/show/NCT00314366

Study 34 – Recruiting Evaluating a Heart Magnetic Resonance Imaging (MRI) Procedure and the Effect of Fish Oil Supplementation in People Who Have Recently Had a Heart Attack (The PROSPECT-CMR Study) Myocardial Infarction http://ClinicalTrials.gov/show/NCT00729430

Diabetes – 5 Active Clinical Trials

Study 1 – Active, not recruiting Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Type I Diabetes http://ClinicalTrials.gov/show/NCT01308437

Study 2 – Active, not recruiting Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes Mellitus Diabetes Mellitus, Type 1 http://ClinicalTrials.gov/show/NCT00883558

Study 3 – Active, not recruiting Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes Type 2 Diabetes Mellitus http://ClinicalTrials.gov/show/NCT00838903

Study 4 – Active, not recruiting A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus http://ClinicalTrials.gov/show/NCT00838916

Study 5 – Active, not recruiting A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes Type 2 Diabetes Mellitus http://ClinicalTrials.gov/show/NCT00839527

Digestive Disorders – 18 Active Clinical Trials

Study 1 – Active, not recruiting A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179) Ulcerative Colitis http://ClinicalTrials.gov/show/NCT00488631

Study 2 – Recruiting Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease Crohn's Disease http://ClinicalTrials.gov/show/NCT01545050

Study 3 – Recruiting

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients Colitis, Ulcerative http://ClinicalTrials.gov/show/NCT01284062

Study 4 – Recruiting B0151003 Open-Label Extension Study Crohn's Disease http://ClinicalTrials.gov/show/NCT01345318

Study 5 – Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo Crohn's Disease http://ClinicalTrials.gov/show/NCT01576471

Study 6 – Active, not recruiting Gender-Stratified Safety and Immunogenicity Study Diarrhea http://ClinicalTrials.gov/show/NCT01067781

Study 7 – Active, not recruiting Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) Short Bowel Syndrome http://ClinicalTrials.gov/show/NCT00930644

Study 8 – Active, not recruiting A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence Crohn's Disease

http://ClinicalTrials.gov/show/NCT01190839

Study 9 – Active, not recruiting A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease Crohn's Disease http://ClinicalTrials.gov/show/NCT00552344

Study 10 – Not Yet recruiting A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease Crohn’s Disease http://ClinicalTrials.gov/show/NCT01769755

Study 11 – Active, not recruiting A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease Crohn's Disease http://ClinicalTrials.gov/show/NCT01155362

Study 12 – Active, not recruiting Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 Crohn's Disease http://ClinicalTrials.gov/show/NCT00686374

Study 13 – Recruiting A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis Ulcerative Colitis http://ClinicalTrials.gov/show/NCT01694485

Study 14 – Active, not recruiting Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease Crohn's Disease http://ClinicalTrials.gov/show/NCT01434693

Study 15 – Active, not recruiting Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis Ulcerative Colitis http://ClinicalTrials.gov/show/NCT00573794

Study 16 – Recruiting The EVICEL® Gastrointestinal Study Gastrointestinal Diseases http://ClinicalTrials.gov/show/NCT01589822

Study 17 – Recruiting Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome Short Bowel Syndrome http://ClinicalTrials.gov/show/NCT00767364

Study 18 – Recruiting

Autologous Stem Cell Transplantation for Crohn's Disease Crohn's Disease http://ClinicalTrials.gov/show/NCT00692939

Eye Disorders – 14 Active Clinical Trials

Study 1 – Recruiting Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Age-Related Macular Degeneration http://ClinicalTrials.gov/show/NCT01024998

Study 2 – Recruiting Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy Age-Related Macular Degeneration http://ClinicalTrials.gov/show/NCT01003691

Study 3 – Recruiting ESBA1008 Safety, Tolerability and Effects in Wet Age-related Macular Degeneration (AMD) Patients Exudative Age-related Macular Degeneration http://ClinicalTrials.gov/show/NCT01304693

Study 4 – Recruiting Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration Dry Age Related Macular Degeneration http://ClinicalTrials.gov/show/NCT01344993

Study 5 – Recruiting Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy Stargardt's Macular Dystrophy http://ClinicalTrials.gov/show/NCT01345006

Study 6 – Not yet recruiting Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients Ligneous Conjunctivitis http://ClinicalTrials.gov/show/NCT01554956

Study 7 – Active, not recruiting

Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema Diabetic Macular Edema http://ClinicalTrials.gov/show/NCT01363440

Study 8 – Not yet recruiting A Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen™ in Patients With Stargardt's Macular Degeneration Stargardt’s Disease http://ClinicalTrials.gov/show/NCT01736592

Study 9 – Active, not recruiting Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration Neovascular Age Related Macular Degeneration http://ClinicalTrials.gov/show/NCT00767949

Study 10 – Active, not recruiting Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration Macular Degeneration http://ClinicalTrials.gov/show/NCT01134055

Study 11 – Active, not recruiting Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) Idiopathic Juxtafoveal Telangiectasia http://ClinicalTrials.gov/show/NCT01327911

Study 12 – Recruiting A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration Age-related Macular Degeneration http://ClinicalTrials.gov/show/NCT01226628

Study 13 – Recruiting Pilot Study of X-82 in Patients With Wet AMD Exudative Macular Degeneration http://ClinicalTrials.gov/show/NCT01674569

Study 14 – Recruiting Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser Diabetic Macular Edema http://ClinicalTrials.gov/show/NCT00491166

Genetic Disorders – 16 Active Clinical trials

Study 1 – Recruiting Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis Cystic Fibrosis http://ClinicalTrials.gov/show/NCT01684410

Study 2 – Recruiting Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment Cystic Fibrosis http://ClinicalTrials.gov/show/NCT01695343

Study 3 – Active, not recruiting A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Fabry Disease http://ClinicalTrials.gov/show/NCT00701415

Study 4 – Recruiting A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia X-linked Hypophosphatemia http://ClinicalTrials.gov/show/NCT01340482

Study 5 – Recruiting An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia X-linked Hypophosphatemia http://ClinicalTrials.gov/show/NCT01571596

Study 6 – Active, not recruiting Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease Pompe Disease http://ClinicalTrials.gov/show/NCT01230801

Study 7 – Not yet recruiting Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis Leber Congenital Amaurosis

http://ClinicalTrials.gov/show/NCT00749957

Study 8 – Active, not recruiting Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Fabry Disease http://ClinicalTrials.gov/show/NCT01218659

Study 9 – Active, not recruiting Safety Study of Replagal® Therapy in Children With Fabry Disease Fabry Disease http://ClinicalTrials.gov/show/NCT01363492

Study 10 – Enrolling by invitation Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease Fabry Disease http://ClinicalTrials.gov/show/NCT01124643

Study 11 – Recruiting Extension Study for Patients Who Have Completed BMN 701 Studies Pompe Disease http://ClinicalTrials.gov/show/NCT01435772

Study 12 – Active, not recruiting Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus- Merzbacher Disease (PMD) Subjects Pelizaeus-Merzbacher Disease http://ClinicalTrials.gov/show/NCT01005004

Study 13 – Active, not recruiting Extension Study of Protocol ENB-006-09 -Asfotase Alfa Treatment in Children With Hypophosphatasia Hypophosphatasia http://ClinicalTrials.gov/show/NCT01203826

Study 14 – Active, not recruiting Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD) Pelizaeus-Merzbacher Disease http://ClinicalTrials.gov/show/NCT01391637

Study 15– Recruiting Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases

Lysosomal Storage Diseases http://ClinicalTrials.gov/show/NCT01003912

Study 16 – Active, not recruiting Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Alpha 1-Antitrypsin Deficiency http://ClinicalTrials.gov/show/NCT00430768

Infectious Diseases – 122 Active Clinical Trials

Study 1 – Recruiting Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age Measles, Mumps and Rubella Diseases http://ClinicalTrials.gov/show/NCT01702428

Study 2 – Active, not recruiting Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants Meningitis, Osteomyelitis, Epiglottis, Cellulitis, Haemophilus Influenzae Type B-Related Disease | Pneumonia http://ClinicalTrials.gov/show/NCT01000974

Study 3 – Active, not recruiting Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine at 12-15 Months of Age Measles, Mumps, Rubella and Varicella Viruses http://ClinicalTrials.gov/show/NCT00861744

Study 4 – Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles- mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Measles, Mumps and Rubella Diseases http://ClinicalTrials.gov/show/NCT01621802

Study 5 – Recruiting

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles- mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Measles, Mumps and Rubella Diseases http://ClinicalTrials.gov/show/NCT01681992

Study 6 – Active, not recruiting Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age H9N2 Pandemic Influenza http://ClinicalTrials.gov/show/NCT01659086

Study 7 – Active, not recruiting Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects Herpes Zoster in HIV-infected Subjects http://ClinicalTrials.gov/show/NCT01165203

Study 8 – Active, not recruiting Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years Herpes Zoster http://ClinicalTrials.gov/show/NCT01165229

Study 9 – Active, not recruiting Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years Herpes Zoster http://ClinicalTrials.gov/show/NCT01165177

Study 10 – Recruiting Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A Herpes Zoster (HZ) http://ClinicalTrials.gov/show/NCT01610414

Study 11 – Active, not recruiting Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Pandemic H5N1 Influenza http://ClinicalTrials.gov/show/NCT01310413

Study 12 – Active, not recruiting

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers Meningococcal Disease http://ClinicalTrials.gov/show/NCT00718666

Study 13 – Active, not recruiting The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults Meningococcal Disease http://ClinicalTrials.gov/show/NCT00715910

Study 14 – Not yet recruiting Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Herpes Zoster http://ClinicalTrials.gov/show/NCT01767467

Study 15 – Active, not recruiting Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Prophylaxis for HPV Infections and Associated Cervical Neoplasia http://ClinicalTrials.gov/show/NCT00294047

Study 16 – Recruiting Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years Staphylococcal Infections | Staphylococcal Vaccines | Bacterial Infections http://ClinicalTrials.gov/show/NCT01643941

Study 17 – Active, not recruiting Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4- Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years Staphylococcal Infections | Staphylococcal Vaccines | Bacterial Infections | Staphylococcal Skin Infections http://ClinicalTrials.gov/show/NCT01364571

Study 18 – Active, not recruiting Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Meningitis | Meningococcal Infection

http://ClinicalTrials.gov/show/NCT00806195

Study 19 – Active, not recruiting Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine Genital Herpes Simplex Type 2 http://ClinicalTrials.gov/show/NCT01667341

Study 20 – Active, not recruiting A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus Healthy http://ClinicalTrials.gov/show/NCT01405885

Study 21 – Active, not recruiting A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine (TetraMen-T) in Infants and Toddlers Meningitis | Meningococcal Infection http://ClinicalTrials.gov/show/NCT01049035

Study 22 – Active, not recruiting A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1 Influenza (Pandemic) http://ClinicalTrials.gov/show/NCT01594320

Study 23 – Active, not recruiting A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2 Influenza (Pandemic) http://ClinicalTrials.gov/show/NCT01596725

Study 24 – Active, not recruiting RSV-F Vaccine Dose Ranging Study in Young Women Respiratory Syncytial Virus (RSV) http://ClinicalTrials.gov/show/NCT01704365

Study 25 – Active, not recruiting Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults Clostridium Difficile Infection | Diarrhea http://ClinicalTrials.gov/show/NCT01230957

Study 26 – Recruiting Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Clostridium Difficile Associated Disease http://ClinicalTrials.gov/show/NCT01706367

Study 27 – Active, not recruiting RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly Respiratory Syncytial Virus (RSV) http://ClinicalTrials.gov/show/NCT01709019

Study 28 – Active, not recruiting Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults Healthy http://ClinicalTrials.gov/show/NCT01250795

Study 29 – Recruiting Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin Hepatitis C http://ClinicalTrials.gov/show/NCT01309932

Study 30 – Recruiting Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children Pneumococcal Disease http://ClinicalTrials.gov/show/NCT01545375

Study 31 – Active, not recruiting Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Yellow Fever http://ClinicalTrials.gov/show/NCT01488890

Study 32 – Active, not recruiting Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Tetanus | Diphtheria | Pertussis | Measles | Polio http://ClinicalTrials.gov/show/NCT01346293

Study 33 – Recruiting Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 & 3 Hepatitis C Virus (HCV) http://ClinicalTrials.gov/show/NCT01616524

Study 34 – Active, not recruiting Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection Clostridium Difficile Infection http://ClinicalTrials.gov/show/NCT01259726

Study 35 – Recruiting Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) Influenza http://ClinicalTrials.gov/show/NCT01773928

Study 36 – Active, not recruiting Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries Encephalitis http://ClinicalTrials.gov/show/NCT01047839

Study 37 – Active, not recruiting A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C Infection http://ClinicalTrials.gov/show/NCT01225380

Study 38 – Recruiting A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age Vaccines | Meningococcal Vaccines http://ClinicalTrials.gov/show/NCT01461980

Study 39 – Active, not recruiting Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years Influenza http://ClinicalTrials.gov/show/NCT01712984

Study 40 – Active, not recruiting A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Hepatitis C, Chronic http://ClinicalTrials.gov/show/NCT01271790

Study 41 – Active, not recruiting A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17 Vaccines | Meningococcal Vaccines http://ClinicalTrials.gov/show/NCT01461993

Study 42 – Recruiting Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses Influenza http://ClinicalTrials.gov/show/NCT01756950

Study 43 – Active, not recruiting Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults Influenza http://ClinicalTrials.gov/show/NCT01612000

Study 44 – Active, not recruiting Norovirus Bivalent-Vaccine Efficacy Study Prevention From Norovirus Infection http://ClinicalTrials.gov/show/NCT01609257

Study 45 – Active, not recruiting Study to Assess the Effect of Adjuvant and Route of Administration on the Safety, Tolerability, and Immunogenicity of NDV-3 Vaccine Against S.Aureus and Candida Staphylococcal Infections | Yeast Infections | Candidiasis http://ClinicalTrials.gov/show/NCT01447407

Study 46 – Recruiting Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects HIV Infections http://ClinicalTrials.gov/show/NCT01428596

Study 47 – Active, not recruiting A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV- 1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) HIV Infections http://ClinicalTrials.gov/show/NCT00532974

Study 48 – Recruiting Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027 AM1) Measles | Mumps | Rubella | Varicella

http://ClinicalTrials.gov/show/NCT01536405

Study 49 – Recruiting Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption HIV Infection http://ClinicalTrials.gov/show/NCT01069809

Study 50 – Recruiting Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine Meningococcal Meningitis http://ClinicalTrials.gov/show/NCT01148017

Study 51 – Active, not recruiting Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Meningitis | Meningococcal Meningitis | Meningococcal Infections | Invasive Meningococcal Disease http://ClinicalTrials.gov/show/NCT01732627

Study 52 – Active, not recruiting Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o. Influenza http://ClinicalTrials.gov/show/NCT00216242

Study 53 – Active, not recruiting Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Vaccines, Pneumococcal Conjugate Vaccine http://ClinicalTrials.gov/show/NCT00980655

Study 54 – Active, not recruiting Persistence Study of GSK Bio's Tdap Vaccine 1, 3, 5 and 10 Years After Administration as a Single Dose in 106316 Study Diphtheria | Pertussis | Tetanus http://ClinicalTrials.gov/show/NCT00489970

Study 55 – Recruiting Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 to 10 Years of Age. Prevention of Meningococcal Disease http://ClinicalTrials.gov/show/NCT01682876

Study 56 – Active, not recruiting Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine Influenza http://ClinicalTrials.gov/show/NCT00521586

Study 57 – Recruiting Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Hepatitis C Virus http://ClinicalTrials.gov/show/NCT01598090

Study 58 – Recruiting A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years Meningitis, Meningococcal http://ClinicalTrials.gov/show/NCT01352793

Study 59 – Recruiting A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Anthrax http://ClinicalTrials.gov/show/NCT01770743

Study 60 – Active, not recruiting Bivalent Norovirus Vaccine Study Gastroenteritis | Infection http://ClinicalTrials.gov/show/NCT01168401

Study 61 – Not yet recruiting Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection Human Immunodeficiency Virus http://ClinicalTrials.gov/show/NCT01734850

Study 62 – Recruiting Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects Human Papillomavirus Infection | Cervical Neoplasia http://ClinicalTrials.gov/show/NCT01190176

Study 63 – Active, not recruiting Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Cholera http://ClinicalTrials.gov/show/NCT01585181

Study 64 – Active, not recruiting ACE393-103 Vaccination Challenge Study Campylobacter Infection http://ClinicalTrials.gov/show/NCT00859716

Study 65 – Recruiting Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Meningococcal Disease http://ClinicalTrials.gov/show/NCT01641042

Study 66 – Recruiting Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study Human Papillomavirus (HPV) Type 16/18 Infections | Cervical Neoplasia http://ClinicalTrials.gov/show/NCT01190189

Study 67 – Recruiting Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) Tuberculosis Infection http://ClinicalTrials.gov/show/NCT01689831

Study 68 – Recruiting Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody Cytomegalovirus Infections http://ClinicalTrials.gov/show/NCT01594437

Study 69 – Active, not recruiting Trial of Yellow Fever Inactivated Vaccine Yellow Fever http://ClinicalTrials.gov/show/NCT00995865

Study 70 – Active, not recruiting Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer Healthy Adult Volunteers http://ClinicalTrials.gov/show/NCT01354379

Study 71 – Recruiting Safety Study of an Oral Vaccine to Prevent Seasonal Influenza Season Influenza http://ClinicalTrials.gov/show/NCT01688297

Study 72 – Recruiting Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected Vaccinia-Naive Adults HIV Infections http://ClinicalTrials.gov/show/NCT01571960

Study 73 – Active, not recruiting H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers Influenza A Subtype H5N1 Infection http://ClinicalTrials.gov/show/NCT01657929

Study 74 – Recruiting A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults Dengue Fever http://ClinicalTrials.gov/show/NCT01666652

Study 75 – Active, not recruiting Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease Dengue Disease | Dengue Fever http://ClinicalTrials.gov/show/NCT01502358

Study 76 – Active, not recruiting Seasonal Influenza HA DNA Vaccine (VRC) and Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children and Adolescents Influenza http://ClinicalTrials.gov/show/NCT01609998

Study 77 – Active, not recruiting Seasonal Influenza HA DNA (VRC) With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults Ages 18-70 Years Influenza http://ClinicalTrials.gov/show/NCT01676402

Study 78 – Active, not recruiting Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone Influenza http://ClinicalTrials.gov/show/NCT01498718

Study 79 – Recruiting

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy Influenza Viral Infections http://ClinicalTrials.gov/show/NCT01666782

Study 80 – recruiting Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease HIV Disease http://ClinicalTrials.gov/show/NCT01731691

Study 81 – Recruiting Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy HIV Infection http://ClinicalTrials.gov/show/NCT00991224 Study 82 – Active, not recruiting Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects HIV Infection http://ClinicalTrials.gov/show/NCT01252641

Study 83 – Active, not recruiting Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Smallpox http://ClinicalTrials.gov/show/NCT00103584

Study 84 – Active, not recruiting Study of Daclatasvir and TMC435 for Subjects With Genotype 1 Chronic Hepatitis C Hepatitis C Virus http://ClinicalTrials.gov/show/NCT01628692

Study 85 – Active, not recruiting A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 Influenza Vaccines http://ClinicalTrials.gov/show/NCT01224262

Study 86 – Recruiting A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis Chronic Hepatitis C Virus http://ClinicalTrials.gov/show/NCT01516918

Study 87 – Recruiting Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects Pandemic H5N1 Influenza http://ClinicalTrials.gov/show/NCT01766921

Study 88 – Active, not recruiting A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment- Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Chronic Hepatitis C Virus Infection http://ClinicalTrials.gov/show/NCT01080222

Study 89 – Not yet recruiting Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children Pandemic H5N1 Influenza http://ClinicalTrials.gov/show/NCT01776554 Study 90 – Active, not recruiting GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Chronic Hepatitis C http://ClinicalTrials.gov/show/NCT01356160

Study 91 – Active, not recruiting Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Chronic Hepatitis C http://ClinicalTrials.gov/show/NCT01371578

Study 92 – Active, not recruiting A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) Hepatitis C http://ClinicalTrials.gov/show/NCT01467479

Study 93 – Recruiting Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease Pneumococcal Conjugate Vaccine http://ClinicalTrials.gov/show/NCT00918580

Study 94 – Not yet recruiting Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Pandemic H5N1 Influenza http://ClinicalTrials.gov/show/NCT01776541

Study 95 – Active, not recruiting Study on Interleukin-7 (CYT107) in HIV Patients HIV Infection http://ClinicalTrials.gov/show/NCT01190111

Study 96 – Recruiting Ciprofloxacin BioThrax Co-Administration Study Anthrax http://ClinicalTrials.gov/show/NCT01753115

Study 97 – Recruiting A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers Dengue http://ClinicalTrials.gov/show/NCT01542632 Study 98 – Recruiting A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART HIV-1 Infection http://ClinicalTrials.gov/show/NCT01378156

Study 99 – Recruiting Re-boosting of HIV-1 Infected Subjects With Vacc-4x HIV-1 Infection http://ClinicalTrials.gov/show/NCT01712256

Study 100 – Active, not recruiting Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Japanese Encephalitis http://ClinicalTrials.gov/show/NCT01246479

Study 101 – Active, not recruiting Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

Chronic Hepatitis B | Chronic Hepatitis C http://ClinicalTrials.gov/show/NCT01708889

Study 102 – Recruiting Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18- 49 Years Influenza http://ClinicalTrials.gov/show/NCT01560793

Study 103 – Active, not recruiting Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune) HIV Infection http://ClinicalTrials.gov/show/NCT00005002

Study 104 – Recruiting Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients HIV Infection http://ClinicalTrials.gov/show/NCT01546818

Study 105 – Recruiting Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum Seasonal Influenza http://ClinicalTrials.gov/show/NCT01761123

Study 106 – Active, not recruiting Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects Anthrax http://ClinicalTrials.gov/show/NCT01265745

Study 107 – Recruiting Immunogenicity of ND1.1 by Delivery Directly to the Ileum Avian Influenza http://ClinicalTrials.gov/show/NCT01698060

Study 108 – Recruiting A Phase 2a Study of GS-6624 in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis Liver Fibrosis | Hepatitis C | HIV Infection http://ClinicalTrials.gov/show/NCT01707472

Study 109 – Active, not recruiting Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults Influenza http://ClinicalTrials.gov/show/NCT01302990

Study 110 – Recruiting Impact of SQ vs IM Administration of DENVax on Safety and Immunogenicity Dengue http://ClinicalTrials.gov/show/NCT01728792

Study 111 – Recruiting Candin Safety & Efficacy Study for the Treatment of Warts Warts | Human Papilloma Virus http://ClinicalTrials.gov/show/NCT01757392

Study 112 – Active, not recruiting Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir HIV Infection http://ClinicalTrials.gov/show/NCT00976404

Study 113 – Recruiting Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) Adenovirus Infection | EBV Infection http://ClinicalTrials.gov/show/NCT00711035

Study 114 – Recruiting Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Immunosenescence | Shingles http://ClinicalTrials.gov/show/NCT01262300

Study 115 – Recruiting Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) Norovirus Infections http://ClinicalTrials.gov/show/NCT01435811

Study 116 – Recruiting Study of Gardasil in Mid-Adult Males (MAM) Human Papillomavirus http://ClinicalTrials.gov/show/NCT01432574

Study 117 – Active, not recruiting Campylobacter Jejuni Challenge Model Development: Dose Ranging Study Campylobacter Infections http://ClinicalTrials.gov/show/NCT00434798

Study 118 – Recruiting Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Subjects With Recurrent Genital Herpes Herpes Simplex Type II http://ClinicalTrials.gov/show/NCT01687595

Study 119 – Recruiting Proof of Biological Activity of SAR100842 in Systemic Sclerosis Systemic Sclerosis http://ClinicalTrials.gov/show/NCT01651143

Study 120 – Recruiting A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease Anemia, Sickle Cell http://ClinicalTrials.gov/show/NCT01597401

Study 121 – Active, not recruiting Safety and Efficacy of T Cell Genetic Immunotherapy for HIV HIV Infection http://ClinicalTrials.gov/show/NCT00131560

Study 122 – Active, not recruiting The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs HIV Infection http://ClinicalTrials.gov/show/NCT00005120

Musculoskeletal Disorders/Arthritis – 33 Active clinical Trials — Rheumatoid Arthritis is listed under Autoimmune Disorders —

Study 1 – Recruiting Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy Psoriatic Arthritis http://ClinicalTrials.gov/show/NCT01490450

Study 2 – Active, not recruiting Study of Adalimumab in Subjects With Axial Spondyloarthritis

Axial Spondyloarthritis http://ClinicalTrials.gov/show/NCT00939003

Study 3 – Active, not recruiting Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Psoriatic Arthritis http://ClinicalTrials.gov/show/NCT01392326

Study 4 – Active, not recruiting Study of Adalimumab in Subjects With Peripheral Spondyloarthritis Peripheral Spondyloarthritis http://ClinicalTrials.gov/show/NCT01064856

Study 5 – Active, not recruiting Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion Degenerative Disc Disease | Degenerative Spondylolisthesis | Spinal Stenosis http://ClinicalTrials.gov/show/NCT00996073

Study 6 – Active, not recruiting Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis Spondyloarthropathies http://ClinicalTrials.gov/show/NCT01087762

Study 7 – Active, not recruiting A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

Low Bone Mineral Density | Osteopenia | Osteoporosis http://ClinicalTrials.gov/show/NCT00515463

Study 8 – Active, not recruiting Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Chronic Discogenic Lumbar Back Pain Degenerative Disc Disease http://ClinicalTrials.gov/show/NCT01290367

Study 9 – Active, not recruiting Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis Psoriatic Arthritis http://ClinicalTrials.gov/show/NCT01087788

Study 10 – Recruiting BOTOX® Treatment in Pediatric Upper Limb Spasticity Muscle Spasticity http://ClinicalTrials.gov/show/NCT01603602

Study 11 – Recruiting A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee. Osteoarthritis http://ClinicalTrials.gov/show/NCT01668511

Study 12 – Recruiting BOTOX® Treatment in Pediatric Lower Limb Spasticity Muscle Spasticity http://ClinicalTrials.gov/show/NCT01603628

Study 13 – Not yet recruiting

Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis Ankylosing Spondylitis http://ClinicalTrials.gov/show/NCT01649375

Study 14 – Recruiting Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects Osteoarthritis | Degenerative Traumatic Injury http://ClinicalTrials.gov/show/NCT01733186

Study 15 – Active, not recruiting Neocartilage Implant Phase III Trial Articular Cartilage Disorder http://ClinicalTrials.gov/show/NCT01400607

Study 16 – Recruiting Confirmatory Study of NeoCart in Knee Cartilage Repair Cartilage Defects of the Femoral Condyle http://ClinicalTrials.gov/show/NCT01066702

Study 17 – Recruiting A Study in Older Participants Who Have Fallen and Have Muscle Weakness Muscle Weakness http://ClinicalTrials.gov/show/NCT01604408

Study 18 – Active, not recruiting Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle Symptomatic Cartilage Defects of the Femoral Condyle http://ClinicalTrials.gov/show/NCT00729716

Study 19 – Active, not recruiting NeoCart Phase 2 Clinical Trial Articular Cartilage Damage http://ClinicalTrials.gov/show/NCT00548119

Study 20 – Active, not recruiting Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis Ankylosing Spondylitis http://ClinicalTrials.gov/show/NCT01109940

Study 21 – Active, not recruiting Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee Osteoarthritis, Knee http://ClinicalTrials.gov/show/NCT01221441

Study 22 – Active, not recruiting Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy Cervical Degenerative Disc Disease | Degenerative Spondylolisthesis | Spinal Stenosis http://ClinicalTrials.gov/show/NCT01097486

Study 23 – Recruiting An Open-label Extension Study With Canakinumab on the Treatment and Prevention of Gout Flares up to 3 Years Chronic Gouty Arthritis http://ClinicalTrials.gov/show/NCT01470989

Study 24 – Active, not recruiting Safety and Efficacy Study of Intravenous Uricase-PEG 20

Gout | Hyperuricemia http://ClinicalTrials.gov/show/NCT01021241

Study 25 – Recruiting Safety and Efficacy Study of Intramuscular Uricase-PEG 20 Gout | Hyperuricemia http://ClinicalTrials.gov/show/NCT01038947

Study 26 – Recruiting BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Muscle Spasticity http://ClinicalTrials.gov/show/NCT01603615

Study 27 – Recruiting BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity Muscle Spasticity http://ClinicalTrials.gov/show/NCT01603641

Study 28 – Recruiting BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity Muscle Spasticity http://ClinicalTrials.gov/show/NCT01575054

Study 29 – Recruiting A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo Degenerative Disc Disease http://ClinicalTrials.gov/show/NCT01771471

Study 30 – Active, not recruiting

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy Alveolar Bone Defects http://ClinicalTrials.gov/show/NCT00755911

Study 31 – Recruiting Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand Osteoarthritis http://ClinicalTrials.gov/show/NCT01683396

Study 32 – Recruiting A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Psoriatic Arthritic http://ClinicalTrials.gov/show/NCT01695239

Study 33 – Recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Systemic Sclerosis http://ClinicalTrials.gov/show/NCT01670565

Neurological Disorders – 18 Active Clinical Trials

Study 1 – Active, not recruiting Study Evaluating ACC-001 in Subjects With Mild To Moderate Alzheimer's Disease Alzheimer’s Disease http://ClinicalTrials.gov/show/NCT00498602

Study 2 – Active, not recruiting

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients Alzheimer's Disease http://ClinicalTrials.gov/show/NCT01097096

Study 3 – Active, not recruiting NP2 Enkephalin For Treatment of Intractable Cancer Pain Intractable Pain | Neoplasms http://ClinicalTrials.gov/show/NCT01291901

Study 4 – Active, not recruiting Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease Alzheimer's Disease http://ClinicalTrials.gov/show/NCT01227564

Study 5 – Recruiting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Chronic Inflammatory Demyelinating Polyneuropathy | Polyradiculoneuropathy http://ClinicalTrials.gov/show/NCT01545076

Study 6 – Recruiting Phase 3 IGIV, 10% in Alzheimer´s Disease Alzheimer’s Disease http://ClinicalTrials.gov/show/NCT01524887

Study 7 – Recruiting A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine Migraine Disorders http://ClinicalTrials.gov/show/NCT01662492

Study 8 – Active, not recruiting Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System Back Pain | Chronic Low Back Pain | Internal Disc Disruption | Degenerative Disc Disease http://ClinicalTrials.gov/show/NCT01011816

Study 9 – Active, not recruiting Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Idiopathic Parkinson's Disease http://ClinicalTrials.gov/show/NCT00985517

Study 10 – Active, not recruiting Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease Alzheimer's Disease http://ClinicalTrials.gov/show/NCT01284387

Study 11 – Active, not recruiting Safety Study of GRNOPC1 in Spinal Cord Injury Spinal Cord Injury http://ClinicalTrials.gov/show/NCT01217008

Study 12 – Active, not recruiting AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder Adhesive Capsulitis | Frozen Shoulder http://ClinicalTrials.gov/show/NCT01483963

Study 13 – Active, not recruiting Gene Transfer for Cancer Pain Cancer Pain http://ClinicalTrials.gov/show/NCT00804076

Study 14 – Recruiting Safety, Efficacy and Pharmacokinetics of ALD403 Migraine http://ClinicalTrials.gov/show/NCT01772524

Study 15 – Active, not recruiting Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers Migraine Disorders http://ClinicalTrials.gov/show/NCT01511497

Study 16 – Active, not recruiting Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury Spinal Cord Injury http://ClinicalTrials.gov/show/NCT01162915

Study 17 – Active, not recruiting Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis http://ClinicalTrials.gov/show/NCT01082653

Study 18 – Recruiting Title Spinocerebellar Ataxia Spinocerebellar Ataxia Type 3 http://ClinicalTrials.gov/show/NCT01350440

Respiratory Diseases – 8 Active Clinical trials

Study 1 – Recruiting Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237- 008) Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal http://ClinicalTrials.gov/show/NCT01678807

Study 2 – Active, not recruiting A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease http://ClinicalTrials.gov/show/NCT01448850

Study 3 – Recruiting A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis http://ClinicalTrials.gov/show/NCT01629667

Study 4 – Active, not recruiting Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies Allergic Rhinitis http://ClinicalTrials.gov/show/NCT00599872

Study 5 – Recruiting CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma Moderate to Severe Allergic Asthma http://ClinicalTrials.gov/show/NCT01673672

Study 6 – Recruiting A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

Allergic Rhinoconjunctivitis http://ClinicalTrials.gov/show/NCT01707069

Study 7 – Recruiting Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids Moderate-to-Severe Asthma http://ClinicalTrials.gov/show/NCT01603277

Study 8 – Recruiting Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis http://ClinicalTrials.gov/show/NCT01266135

Skin Diseases – 15 Active Clinical Trials Skin cancer clinical trials are listed under Cancer

Study 1 – Recruiting Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Hidradenitis Suppurativa (HS) http://ClinicalTrials.gov/show/NCT01468207

Study 2 – Recruiting Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Hidradenitis Suppurativa (HS) http://ClinicalTrials.gov/show/NCT01468233

Study 3 – Active, not recruiting Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens Moderate to Severe Plaque-type Psoriasis http://ClinicalTrials.gov/show/NCT01406938

Study 4 – Recruiting Evaluation of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes Lower Extremity Chronic Ulcers in Diabetics http://ClinicalTrials.gov/show/NCT01421966

Study 5 – Recruiting Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers Venous Leg Ulcers http://ClinicalTrials.gov/show/NCT01656889

Study 6 – Recruiting Study of ACCS (Amnion-derived Cellular Solution) in Diabetic Subjects With Deep Burns Managed With Skin Grafts Deep Burns in Subjects With Diabetes http://ClinicalTrials.gov/show/NCT01715012

Study 7 – Recruiting Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery Scar Formation http://ClinicalTrials.gov/show/NCT01053897

Study 8 – Recruiting

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing Epidermolysis Bullosa http://ClinicalTrials.gov/show/NCT01749306

Study 9 – Active, not recruiting StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns Skin Wound | Burns | Infection Related Wound | Trauma-related Wound http://ClinicalTrials.gov/show/NCT01437852

Study 10 – Active, not recruiting A Study in Participants With Moderate to Severe Psoriasis Psoriasis http://ClinicalTrials.gov/show/NCT01107457

Study 11 – Recruiting Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa Hidradenitis Suppurativa http://ClinicalTrials.gov/show/NCT01635764

Study 12 – Recruiting Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents Contact Dermatitis http://ClinicalTrials.gov/show/NCT01518348

Study 13 – Not yet recruiting Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging Intrinsic Aging of Skin | Chronic Effect of Ultraviolet Radiation on Normal Skin | Dermatologic Disorders

http://ClinicalTrials.gov/show/NCT01771679

Study 14 – Recruiting Study of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline in Treating Skin Irritation From Radiation Radiation-induced Dermatitis http://ClinicalTrials.gov/show/NCT01714973

Study 15 – Recruiting Use of Botulinum Toxin to Treat Psoriasis Psoriasis Vulgaris http://ClinicalTrials.gov/show/NCT00816517

Transplantation – 5 Active Clinical trials

Study 1 – Active, not recruiting Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) Acute GvHD http://ClinicalTrials.gov/show/NCT01530256

Study 2 – Recruiting Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) GVHD | Adult Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Myelodysplastic Syndrome http://ClinicalTrials.gov/show/NCT01295710

Study 3 – Recruiting A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection Graft Rejection http://ClinicalTrials.gov/show/NCT01147302

Study 4 – Active, not recruiting Visilizumab in Treating Patients With Graft-Versus-Host Disease Following Donor Stem Cell Transplantation Graft Versus Host Disease http://ClinicalTrials.gov/show/NCT00042744

Study 5 – Recruiting Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection Kidney Transplantation http://ClinicalTrials.gov/show/NCT01134510

Other – 49 Active Clinical trials

Study 1 – Recruiting Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Peanut Allergy http://ClinicalTrials.gov/show/NCT01675882

Study 2 – Recruiting Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy Median Sternotomy http://ClinicalTrials.gov/show/NCT01657045

Study 3 – Recruiting A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers Healthy http://ClinicalTrials.gov/show/NCT01740609

Study 4 – Recruiting A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects Healthy http://ClinicalTrials.gov/show/NCT01616277

Study 5 – Recruiting GS-6624 in the Treatment of Cirrhosis Due to NASH Non-Alcoholic Steatohepatitis (NASH) http://ClinicalTrials.gov/show/NCT01672879

Study 6 – Recruiting A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Chronic Kidney Disease | Chronic Renal Failure http://ClinicalTrials.gov/show/NCT01473407

Study 7 – Enrolling by invitation Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (Study P06031) Infertility http://ClinicalTrials.gov/show/NCT01146418

Study 8 – Recruiting A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Chronic Renal Failure | Chronic Kidney Disease http://ClinicalTrials.gov/show/NCT01473420

Study 9 – Recruiting A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects Acute Kidney Injury http://ClinicalTrials.gov/show/NCT01602328

Study 10 – Not yet recruiting

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2 Venous Leg Ulcers http://ClinicalTrials.gov/show/NCT01737762

Study 11 – Not yet recruiting Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Lupus Nephritis http://ClinicalTrials.gov/show/NCT01714817

Study 12 – Recruiting Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Overactive Bladder http://ClinicalTrials.gov/show/NCT00439140

Study 13 – Active, not recruiting Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery Kidney Tubular Necrosis, Acute http://ClinicalTrials.gov/show/NCT00733876

Study 14 – Active, not recruiting Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients Chronic Kidney Disease http://ClinicalTrials.gov/show/NCT00985426

Study 15 – Recruiting A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers Healthy http://ClinicalTrials.gov/show/NCT01710826

Study 16 – Active, not recruiting A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis Overactive Bladder http://ClinicalTrials.gov/show/NCT00876447

Study 17 – Recruiting

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse Methamphetamine Abuse http://ClinicalTrials.gov/show/NCT01603147

Study 18 – Recruiting A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GI-13020 at Various Dose Levels and Regimens in Healthy Adults. Healthy Volunteers http://ClinicalTrials.gov/show/NCT01779505

Study 19 – Active, not recruiting Efficacy of NicVAX in Smokers Who Want to Quit Smoking Smoking Cessation http://ClinicalTrials.gov/show/NCT00318383 Study 20 – Active, not recruiting Improving the Efficacy of Anti-Nicotine Immunotherapy Nicotine Dependence http://ClinicalTrials.gov/show/NCT01280968

Study 21– Recruiting Open-Label Study of Asfotase Alfa (ENB-0040) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) Hypophosphatasia http://ClinicalTrials.gov/show/NCT01176266

Study 22 – Recruiting A Phase 3 Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Chronic Renal Failure Requiring Hemodialysis http://ClinicalTrials.gov/show/NCT01628107

Study 23 – Active, not recruiting Tolerability and Safety of Immune Globulin Subcutaneous Solution and rHuPH20 in Primary Immunodeficiency Diseases (PID) Primary Immunodeficiency Diseases http://ClinicalTrials.gov/show/NCT01175213

Study 24 – Recruiting A Phase 3 Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Chronic Renal Failure Requiring Hemodialysis http://ClinicalTrials.gov/show/NCT01628120

Study 25 – Recruiting Study to Assess the Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures Dupuytren's Contracture http://ClinicalTrials.gov/show/NCT01674634

Study 26 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness http://ClinicalTrials.gov/show/NCT01669746

Study 27 – Recruiting Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders Urea Cycle Disorders http://ClinicalTrials.gov/show/NCT01195753

Study 28 – Recruiting A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks Phenylketonuria http://ClinicalTrials.gov/show/NCT01560286

Study 29 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness http://ClinicalTrials.gov/show/NCT01451190

Study 30 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness http://ClinicalTrials.gov/show/NCT01451125

Study 31 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness http://ClinicalTrials.gov/show/NCT01451138

Study 32 – Active, not recruiting

Extension Study of Protocol ENB-002-08 - Asfotase Alfa Treatment in Severely Affected Infants and Young Children With Hypophosphatasia (HPP) Hypophosphatasia http://ClinicalTrials.gov/show/NCT01205152

Study 33 – Active, not recruiting Administration of Two Injections for Multiple Dupuytren's Contractures Dupuytren's Contracture http://ClinicalTrials.gov/show/NCT01407068

Study 34 – Active, not recruiting Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil Bilateral Ovarian Disease http://ClinicalTrials.gov/show/NCT00544310

Study 35 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness http://ClinicalTrials.gov/show/NCT01451112

Study 36 – Not yet recruiting Phase 1b Study Investigating Safety & Immunogenicity of DENVax Given Intradermally by Needle or Needle Free PharmaJet Injector Normal Healthy Adult http://ClinicalTrials.gov/show/NCT01765426

Study 37 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness

http://ClinicalTrials.gov/show/NCT01451151

Study 38 – Active, not recruiting A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness http://ClinicalTrials.gov/show/NCT01451177

Study 39 – Active, not recruiting The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Edematous Fibrosclerotic Panniculopathy|Cellulite http://ClinicalTrials.gov/show/NCT01518907

Study 40 – Active, not recruiting Pilot Study of GS-6624 in the Treatment of Liver Fibrosis Liver Fibrosis http://ClinicalTrials.gov/show/NCT01452308

Study 41 – Not yet recruiting A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence Overactive Bladder | Urinary Incontinence http://ClinicalTrials.gov/show/NCT01767519

Study 42 – Active, not recruiting Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure Hematopoietic Syndrome Due to Acute Radiation Syndrome http://ClinicalTrials.gov/show/NCT01742221

Study 43 – Active, not recruiting Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Overactive Bladder | Urinary Incontinence http://ClinicalTrials.gov/show/NCT00915525

Study 44 – Not yet recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Acute Alcoholic Hepatitis http://ClinicalTrials.gov/show/NCT01471028

Study 45 – Not yet recruiting Efficacy of Iocide Oral Rinse Against Gingival Inflammation Gingivitis http://ClinicalTrials.gov/show/NCT01782170

Study 46 – Active, not recruiting Rituximab + Immune Globulin Intravenous (IVIG) for Desensitization End Stage Renal Disease http://ClinicalTrials.gov/show/NCT01178216

Study 47 – Active, not recruiting Mepolizumab As a Steroid-Sparing Treatment Option in the Churg Strauss Syndrome Churg Strauss Syndrome http://ClinicalTrials.gov/show/NCT00527566

Study 48 – Not yet recruiting A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty Rhinoplasty http://ClinicalTrials.gov/show/NCT01684020

Study 49 – Recruiting Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis Urinary Incontinence | Multiple Sclerosis http://ClinicalTrials.gov/show/NCT01600716